STOCK TITAN

Nyxoah SA Ordinary Shares - NYXH STOCK NEWS

Welcome to our dedicated page for Nyxoah SA Ordinary Shares news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah SA Ordinary Shares stock.

Nyxoah SA Ordinary Shares (symbol: NYXH) is at the forefront of medical technology, focusing on innovative solutions to address Obstructive Sleep Apnea (OSA). The company is committed to enhancing the lives of individuals suffering from sleep-disordered breathing conditions through its state-of-the-art products and services.

Nyxoah's flagship product, the Genio system, is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe OSA. This user-centered system provides an effective and non-invasive treatment option for a condition that has been linked to increased mortality risks and various comorbidities, including cardiovascular diseases, depression, and stroke.

The Genio system stands out in the market due to its unique approach, focusing on bilateral stimulation to open the airway during sleep, thereby improving the quality of life for patients. The development and commercialization of this innovative platform underscore Nyxoah's commitment to addressing critical health issues with cutting-edge technology.

Recent achievements of Nyxoah include advancements in clinical trials, expansion into new markets, and strategic partnerships that underscore the company's growth potential and dedication to innovation. Financially, Nyxoah has shown resilience and strategic foresight, ensuring robust investment in research and development to maintain its competitive edge.

Nyxoah continually updates its stakeholders with the latest company news, ensuring transparency and fostering investor confidence. With its headquarters in Belgium, Nyxoah is well-positioned to expand its global presence and continue its mission of providing effective solutions for OSA and related conditions.

Stay informed with the latest updates and developments from Nyxoah to keep track of their performance, events, and strategic initiatives.

Rhea-AI Summary

Nyxoah announced that its BETTER SLEEP clinical trial met its primary endpoint, demonstrating the effectiveness of hypoglossal nerve stimulation (HGNS) for treating patients with Complete Concentric Collapse (CCC) of the soft palate. The trial involved 42 moderate-to-severe obstructive sleep apnea patients, with a statistically significant reduction in apnea-hypopnea index (AHI4) of 11 points at six months. Over 60% responder rates were achieved across patient cohorts. The company aims for expanded therapeutic indications and ongoing collaboration with the FDA for clinical trials in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
none
-
Rhea-AI Summary

Nyxoah SA announced its participation in the Oppenheimer 32nd Annual Healthcare Conference, scheduled for March 15-17, 2022. The company will present virtually with CEO Olivier Taelman providing a corporate update on March 16 at 10:40 am EST. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA) treatment, notably through its lead product, the Genio® system. This system received its CE Mark in 2019 and is currently being studied for FDA approval. Investors can access the live webcast and updated presentations via the company's investor relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
-
Rhea-AI Summary

Nyxoah announced its participation at the World Sleep Congress 2022 in Rome, Italy, from March 11-16, 2022. The company will present data from its BETTER SLEEP clinical trial on March 14 and hold several physician events. The Genio® system, a breakthrough treatment for Obstructive Sleep Apnea (OSA), was highlighted. Nyxoah aims to improve therapies for patients with Complete Concentric Collapse (CCC) and is working towards securing FDA approval for clinical trials for CCC patients in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Nyxoah SA will announce its 2021 financial results on March 24, 2022, after market close. A conference call for discussion is scheduled for March 25, 2022, at 2:00 PM CET / 8:00 AM ET. Investors can join by phone or via the company's investor relations website. Nyxoah specializes in treating Obstructive Sleep Apnea with its innovative Genio® system, which received CE Mark approval in 2019 and is currently under study for FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
-
Rhea-AI Summary

Nyxoah SA has disclosed updated information on its voting rights and share capital as of February 11, 2022. The total share capital stands at EUR 4,431,664.69, with 25,797,359 ordinary shares now carrying voting rights. Furthermore, the company has several outstanding subscription rights, including 55 warrants from 2016 for 27,500 shares, 100 warrants from 2018 for 50,000 shares, 490,500 warrants from 2020 for 490,500 shares, and 1,400,000 warrants from 2021. This update complies with Article 15 of the Law of 2 May 2007 on large shareholdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Nyxoah SA (NASDAQ: NYXH) announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022. CEO Olivier Taelman will deliver a corporate update on February 17, 2022, at 8:00 AM EST. The presentation will not be webcast, but Nyxoah will hold virtual 1x1 meetings with registered institutional investors. The company specializes in innovative treatments for Obstructive Sleep Apnea (OSA), with its lead product, Genio®, receiving CE Mark approval after the successful completion of the BLAST OSA study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
conferences
News
Rhea-AI Summary

Nyxoah announced updates following a transformational 2021 that set the stage for advances in 2022. Key highlights include:

  • 15 U.S. patient sites active in the DREAM IDE pivotal study.
  • Secured CE Mark MR conditional labeling for Genio® system.
  • Raised $97.8 million from a Nasdaq IPO.
  • FDA Breakthrough Device Designation granted for OSA treatment.
  • Expanded CE Mark indication, increasing market potential by over 30%.
  • Strong commercial progress in Germany and Switzerland.

CEO Olivier Taelman expressed optimism for continued growth and market leadership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Nyxoah SA disclosed its current share capital and voting rights information following the exercise of subscription rights. As of November 26, 2021, the share capital stands at EUR 4,427,369.69, with a total of 25,772,359 ordinary shares carrying voting rights. Additionally, the report outlines outstanding subscription rights from previous employee stock option plans, including a total of 1,400,000 securities available through the 2021 ESOP Warrants, issued on September 8, 2021. This transparency complies with the Law on the disclosure of large shareholdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary

Nyxoah has announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021. CEO Olivier Taelman will participate in a fireside chat, accessible via the company's investor relations website. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA), with its lead product, the Genio® system, receiving a European CE Mark in 2019. The company is also conducting the DREAM IDE pivotal study for FDA approval to advance its offerings in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News
Rhea-AI Summary

Nyxoah Announces New CFO Appointment

Mont-Saint-Guibert, Belgium – November 8, 2021 - Nyxoah (NYSE: NYXH) appointed Loïc Moreau as its new CFO, effective January 1, 2022. Moreau joins from GSK, where he held significant finance roles. He replaces Fabian Suarez, who is leaving to become CEO of a MedTech startup. CEO Olivier Taelman expressed gratitude for Suarez's contributions, particularly during the company's IPOs on Euronext and Nasdaq. Nyxoah specializes in innovative treatments for Obstructive Sleep Apnea, and its Genio® system has achieved CE Mark approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
management

FAQ

What is the current stock price of Nyxoah SA Ordinary Shares (NYXH)?

The current stock price of Nyxoah SA Ordinary Shares (NYXH) is $8.01 as of December 20, 2024.

What is the market cap of Nyxoah SA Ordinary Shares (NYXH)?

The market cap of Nyxoah SA Ordinary Shares (NYXH) is approximately 298.7M.

What is Nyxoah SA's core business?

Nyxoah SA focuses on developing and commercializing innovative solutions to treat Obstructive Sleep Apnea (OSA).

What is the Genio system?

The Genio system is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe Obstructive Sleep Apnea (OSA).

What conditions does Nyxoah's Genio system address?

The Genio system targets Obstructive Sleep Apnea (OSA), which is associated with increased mortality risk and comorbidities like cardiovascular diseases, depression, and stroke.

How does Nyxoah update its stakeholders?

Nyxoah ensures transparency by continually updating stakeholders with the latest company news, performance information, and strategic initiatives.

Where is Nyxoah SA headquartered?

Nyxoah SA is headquartered in Belgium, with its innovative solutions reaching markets worldwide.

What makes the Genio system unique?

The Genio system is unique due to its bilateral stimulation approach, providing an effective and non-invasive treatment for OSA by opening the airway during sleep.

What recent achievements has Nyxoah accomplished?

Nyxoah has made significant strides in clinical trials, market expansion, and strategic partnerships, highlighting its growth potential and commitment to innovation.

What is OSA?

Obstructive Sleep Apnea (OSA) is a sleep disorder characterized by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to breathing interruptions.

Why invest in Nyxoah SA?

Nyxoah SA offers innovative solutions for OSA, a condition with significant health risks. The company's continuous advancements, strategic partnerships, and commitment to innovation make it a promising investment opportunity.

What are Nyxoah's future plans?

Nyxoah aims to expand its global presence, enhance its product offerings, and continue investing in research and development to bring effective solutions for sleep-disordered breathing conditions.

Nyxoah SA Ordinary Shares

Nasdaq:NYXH

NYXH Rankings

NYXH Stock Data

298.67M
22.46M
41.74%
35.37%
0.12%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Mont-Saint-Guibert